MS treatment breakthrough? study tests if patients can safely step down powerful drugs
NCT ID NCT07189325
Summary
This study aims to find out if people with stable relapsing-remitting multiple sclerosis (MS) who are over 40 years old can safely switch from a strong, long-term medication (anti-CD20 therapy) to a milder one. Researchers want to see if switching reduces side effects and infection risks without letting the MS get worse. They will compare two groups of 250 patients: one stays on the strong drug, and the other switches to a milder treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSING REMITTING MULTIPLE SCLEROSIS (RRMS) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Neurology Department, Hospital Gui de Chauliac
Montpellier, 34295, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.